[144] NewAmsterdam Pharma Company N.V. Warrant SEC Filing

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. (NAMSW) Rule 144 notice: The filing reports a proposed sale of 100,000 ordinary shares (nominal value EUR 0.12) through ABN AMRO on the Nasdaq Global Market with an aggregate market value of $2,500,000.00. The filer acquired these shares by option exercise on 03/24/2025 from NewAmsterdam Pharma Company N.V., paid in cash on 03/11/2025. The filing shows prior sales by the same person of 50,000 shares on 08/21/2025 for $1,214,613.94 and 50,000 shares on 08/22/2025 for $1,257,092.68. Total shares outstanding are reported as 112,628,458. The filer certifies no undisclosed material adverse information.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 disclosure of an option exercise and proposed sale; appears procedural rather than material.

The notice documents a proposed sale under Rule 144 of 100,000 ordinary shares acquired by option exercise. It identifies the broker, exchange, acquisition date, payment method, and recent sales by the same person. This filing satisfies Rule 144 disclosure mechanics by detailing acquisition, form of payment, and aggregation of recent sales. There is no information in the filing indicating undisclosed material operational or financial developments at the issuer, and the filer affirms no material adverse information is known. From a compliance perspective, the form appears complete for its purpose.

Equity Capital Markets Analyst

TL;DR: Transaction size is small relative to outstanding shares; likely low market impact.

The proposed 100,000-share sale equals roughly 0.089% of the reported 112,628,458 shares outstanding, with prior intraday sales of two 50,000-share blocks also disclosed. Given the small proportion of the float and absence of issuer financials or operational events in this notice, the filing itself is unlikely to be market-moving. It provides price and timing context for recent disposals, helping market participants understand potential selling pressure from this holder in the short term.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, nominal value EUR 0.12 per share	ABN AMRO Gustav Mahlerlaan 10 Amsterdam P7 1082 PP	100000	2500000.00	112628458	08/21/2025	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, nominal value EUR 0.12 per share	03/24/2025	Option Exercise	NewAmsterdam Pharma Company N.V.			100000	03/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Johannes Jacob Pieter Kastelein Gooimeer 2-35 Naarden P7 1411 DC	Ordinary shares, nominal value EUR 0.12 per share	08/21/2025	50000	1214613.94
Johannes Jacob Pieter Kastelein Gooimeer 2-35 Naarden P7 1411 DC	Ordinary shares, nominal value EUR 0.12 per share	08/22/2025	50000	1257092.68

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Rule 144 filing for NewAmsterdam Pharma (NAMSW) report?

The filing reports a proposed sale of 100,000 ordinary shares on Nasdaq Global Market through ABN AMRO with an aggregate market value of $2,500,000.00.

How and when were the shares being sold in the NAMSW Rule 144 notice acquired?

The 100,000 shares were acquired by option exercise on 03/24/2025 from NewAmsterdam Pharma Company N.V., with payment in cash on 03/11/2025.

What recent sales by the same person are disclosed in the filing?

The filing discloses sales of 50,000 shares on 08/21/2025 for $1,214,613.94 and 50,000 shares on 08/22/2025 for $1,257,092.68.

How many shares outstanding does the filing report for NAMSW?

The filing reports 112,628,458 shares outstanding for the issuer.

Who is the broker named in the Form 144 for NAMSW?

The broker listed is ABN AMRO (address: Gustav Mahlerlaan 10 Amsterdam).